LCTX Stock Analysis: Buy, Sell, or Hold?
LCTX - Lineage Cell Therapeutics, Inc.
$1.65
-0.06 (-3.51%)
▼
5d:
+9.27%
30d:
+6.45%
90d:
-2.94%
HOLD
MODERATE Confidence
Analysis Updated: Apr 20, 2026 12:00 AM ET
Earnings: May 12, 2026
20d
Smart Money Accumulation
LCTX is down 5.7% this week, but smart money is accumulating calls. Top strike: $2 2026-06-18 with 4,739 OI. Call ratio: 100% View Scanner →
Strength: 7.9/10
Get Alerted When LCTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: LCTX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: LCTX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: LCTX is currently trading at $1.65, which is considered extended relative to its 30-day fair value range of $1.49 to $1.62.
Technical Outlook: Technically, LCTX is in a strong uptrend. Immediate support is located at $1.45, while resistance sits at $1.75. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: LCTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $4.50 (+172.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, LCTX is in a strong uptrend. Immediate support is located at $1.45, while resistance sits at $1.75. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: LCTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $4.50 (+172.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$1.49 -
$1.62
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.5%)
- BULLISH: Trading 172.7% below Wall St target ($4.50)
Fair Price Analysis
30-Day Fair Range
$1.49 -
$1.62
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$1.45
Resistance Level
$1.75
Current Trend
Strong Uptrend
Technical data as of
Apr 20, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-21.29
Wall Street Target
$4.50
(+172.7%)
Revenue Growth (YoY)
130.4%
Share & Embed Analysis
Last updated: April 21, 2026 5:06 AM ET
Data refreshes hourly during market hours. Next update: 6:06 AM
Data refreshes hourly during market hours. Next update: 6:06 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LCTX showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Brian M Culley
BUY
15000 shares
2026-03-12
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$89 | 57 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$98 | 65 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$93 | 61 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 64 BUY |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
